

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S
Form 6-K
July 03, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

July 03 2007

NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)

NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b): 82-_____

TREASURY STOCK

STATUS RE NOVO NORDISK'S HOLDING OF ITS OWN SHARES (30 JUNE 2007)

In continuation of the company's announcement dated 31 January 2007 concerning a
planned share repurchase programme, and pursuant to Section 204.25 of the New
York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk
A/S (NYSE: NVO) and its wholly-owned affiliates on 30 June 2007 owned 5,514,614

Edgar Filing: NOVO NORDISK A S - Form 6-K

of its own B shares of DKK 2, corresponding to a total nominal value of DKK 11,029,228 or 1.70% of the total share capital. Hereof the wholly-owned affiliates owned 99,000 B shares of DKK 2, corresponding to a total nominal value of DKK 198,000 or 0.03% of the total share capital.

In the second quarter of 2007 138,000 B shares were repurchased by Novo Nordisk A/S, and 306,695 B shares were disposed of to employees who exercised options granted by Novo Nordisk. In addition 13,480,000 own B shares were cancelled on 19 June 2007.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 25,300 full-time employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

For further information please contact:

Investors:

Media:

Outside North America:

Elin K Hansen

Tel: (+45) 4442 3450
ekh@novonordisk.com

Outside North America:

Mads Veggerby Lausten

Tel: (+45) 4443 7919
mlau@novonordisk.com

Hans Rommer
Tel: (+45) 4442 4765
hrrmm@novonordisk.com

In North America:

Lori Moore

Tel: (+1) 609 919 7991
lrmo@novonordisk.com

In North America:

Christian Qvist Frandsen

Tel: (+1) 609 919 7937
cqfr@novonordisk.com

Stock Exchange Announcement no 19/2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Edgar Filing: NOVO NORDISK A S - Form 6-K

Date: July 03 2007

NOVO NORDISK A/S

Lars Rebien Sorensen,
President and Chief Executive Officer